Manufacturing Sterile Products
to Meet EU and FDA Guidelines
In drug and device manufacturing, sterile means precisely what it says: The total absence of viable microorganisms. Obviously, not everyone is meeting this standard:
A meningitis outbreak kills 64 in 20 states. It is traced back to steroidal injections manufactured by a New England compounding center.
A Nevada-based compounder recalls all its sterile compounded products after the FDA issues warning for lack of sterility assurance and general quality control.
A China-based contract manufacturer and contract sterilizer, receives a warning letter for shortfalls in sterilization validation.
Poor microbial contamination control is now a top Form 483 observation. The focus to date has been on compounding pharmacies, but no FDA- or EU-regulated manufacturer is exempt from its country’s purity laws.
Now’s the time for a hard look at your manufacturing processes.
This timely new management report from FDAnews spells out how U.S. and EU manufacturers must handle sterile processing, focusing first on the basics:
Qualified and well-trained personnel
Suitable production equipment
Validated methods for all critical manufacturing steps
Documentation of environmental conditions and in-process controls
You’ll examine in-depth the two methods to manufacture sterile medicinal products:
Equally important — primary product packaging. This report offers clear guidance to the appropriate package sterilization method for every sterile product you offer.
Here’s just a sampling of specifics covered:
FDA and EU regulatory requirements sterile products must meet
How to set up workspaces and carry out manufacturing of terminally sterilized products
How to set up workspaces and manufacture sterile products under aseptic conditions
Cleanliness grades for clean rooms, personnel and materials, and how to achieve them
How to design and construct air locks to ensure the quality of clean room conditions
How to conduct risk-based validation for all sterile processes to meet GMP requirements
Advantages and disadvantages of common filling methods
How to prepare, implement, document and report a media fill
Measures to take when acceptance criteria are exceeded
About the freeze-drying process, including qualification and validation
About microbiological monitoring, including methods, equipment and contamination sources
And much more
The New England Compounding Center (NECC) has just agreed to a $100 million settlement in the meningitis case. That’s the last thing your company wants to face.
Save money with a license agreement allowing significant numbers of users access to an electronic version of this book. For multi-user access to multiple titles, FDAnews offers the FDAnews Online Library — a personalized collection of FDAnews publications that is fully searchable. Contact Customer Service for a quote or more information.
Not satisfied with your publication? For the PDF version, you must notify FDAnews within 24 hours of receipt of purchase and we will refund 100 percent of your purchase price.